SEYSARA (sarecycline)

About Paratek Pharmaceuticals

Paratek Pharmaceuticals is a mission-driven, commercial-stage biopharma focused on creating 'Positive Patient Stories®' by tackling serious infectious diseases and chronic inflammatory conditions. The company has successfully transitioned from R&D to a fully integrated commercial entity with two marketed products: NUZYRA® (omadacycline), a modern tetracycline antibiotic, and XHANCE® (fluticasone propionate), a novel-delivery nasal spray. Its strategy leverages deep expertise in tetracycline chemistry and targeted drug delivery to serve substantial specialty markets while addressing critical public health threats like antimicrobial resistance.

About Almirall

Almirall is a publicly traded, revenue-generating pharmaceutical company with a singular strategic focus on becoming a global leader in medical dermatology. The company has successfully transformed from a broad-based pharma player into a specialized dermatology entity, leveraging deep internal R&D, strategic partnerships, and a direct commercial infrastructure. Its mission is to deliver innovative science to improve the lives of patients with skin conditions, supported by a growing portfolio of marketed products and a promising clinical pipeline.

Therapeutic Areas